A total of 30 cases were included in the study. The patients were divided into two groups as responders and non-responders. The group of responders was evaluated in three categories as patients with response, stable disease and flare phenomenon based on the PSA working group consensus criteria as follows: a) Response: ≥50% PSA reduction from baseline, b) Stable disease: <50-0% PSA reduction from baseline or absence of any reduction, c) Flare phenomenon: ≥50% PSA reduction from baseline followed by increased PSA levels with subsequent PSA reduction below the baseline values.8 In addition, patients were also stratified into two groups according to GS as the intermediate-risk group (GS: 7) and the as high-risk group (GS: 8-10).1,9